Rigel Pharmaceuticals Inc. (New) financials
$48.89−0.95%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $294.3M | $179.3M | $116.9M | $120.2M | $149.2M | $108.6M | $59.3M | $44.5M | $4.5M | $20.4M |
| Gross profit | $274.7M | $160.6M | $109.8M | $118.5M | $148.2M | $107.7M | $58.4M | $44.2M | $4.5M | $20.4M |
| Gross margin | 93.3% | 89.6% | 93.9% | 98.5% | 99.3% | 99.2% | 98.5% | 99.4% | 100.0% | 100.0% |
| Operating income | $125.5M | $24.2M | -$20.5M | -$55.5M | -$12.5M | -$29.0M | -$69.1M | -$72.7M | -$79.6M | -$69.7M |
| Net income | $367.0M | $17.5M | -$25.1M | -$58.6M | -$17.9M | -$29.7M | -$66.9M | -$70.5M | -$78.0M | -$69.2M |
| Net margin | 124.7% | 9.8% | −21.5% | −48.7% | −12.0% | −27.4% | −112.8% | −158.3% | −1739.3% | −339.6% |
| Diluted EPS | $19.48 | $0.99 | $-1.44 | $-3.44 | $-0.11 | $-0.18 | $-4.00 | $-4.40 | $-6.20 | $-7.30 |
| EBITDA | $127.9M | $26.4M | -$19.3M | -$53.2M | -$7.8M | -$28.3M | -$68.4M | -$72.1M | -$79.2M | -$63.0M |
| Operating cash flow | $75.7M | $31.5M | -$5.7M | -$73.8M | $5.9M | -$52.2M | -$41.5M | -$58.8M | -$77.6M | -$75.9M |
| Free cash flow | $75.7M | $31.4M | -$5.7M | -$74.2M | $5.3M | -$53.4M | -$43.0M | -$59.9M | -$77.7M | -$76.7M |
| Diluted shares | 18.8M | 17.7M | 17.4M | 17.0M | 170.5M | 168.8M | 16.7M | 16.1M | 12.6M | 9.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $40.6M | $56.7M | $32.8M | $24.5M | $18.9M | $30.4M |
| Short-term investments | $114.4M | $20.6M | $24.1M | $33.7M | $106.1M | $27.0M |
| Total debt | $52.3M | $59.7M | $59.6M | $39.4M | $19.9M | $19.8M |
| Total assets | $513.6M | $164.0M | $117.2M | $134.3M | $167.3M | $110.4M |
| Total liabilities | $122.1M | $160.7M | $145.9M | $147.9M | $137.0M | $76.4M |
| Shareholders' equity | $391.5M | $3.3M | -$28.6M | -$13.6M | $30.4M | $34.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology